Initial treatment patterns over time for anaplastic oligodendroglial tumors

Neuro-Oncology

Volumn 14, Issue 6, 2012, Pages 761-767

  Panageas, Katherine S ^a   Iwamoto, Fabio M ^a,r   Cloughesy, Timothy F ^b   Aldape, Kenneth D ^c   Rivera, Andreana L ^c,s   Eichler, April F ^d   Louis, David N ^d   Paleologos, Nina A ^e   Fisher, Barbara J ^f   Ashby, Lynn S ^g   Gregory Cairncross, J ^h   Urgoiti, Gloria B Roldán ^h   Wen, Patrick Y ⁱ   Ligon, Keith L ^j   Schiff, David ^k   Ian Robins, H ^l   Rocque, Brandon G ^l   Chamberlain, Marc C ^m   Mason, Warren P ⁿ   Weaver, Susan A ^o   Green, Richard M ^p   Kamar, Francois G ^q   Abrey, Lauren E ^a,t,u   DeAngelis, Lisa M ^a   Jhanwar, Suresh C ^a   Rosenblum, Marc K ^a   Lassman, Andrew B ^a,r   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f LONDON REGIONAL CANCER PROGRAM   (Canada)

^g BARROW NEUROLOGICAL INSTITUTE   (United States)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^l UNIVERSITY OF WISCONSIN MADISON   (United States)

^m Fred Hutchinson Cancer Research Center   (United States)

ⁿ PRINCESS MARGARET HOSPITAL   (Canada)

^o ALBANY MEDICAL CENTER   (United States)

^p KAISER PERMANENTE MEDICAL CENTER   (United States)

^q HOLY SPIRIT UNIVERSITY OF KASLIK USEK   (Lebanon)

^r NewYork Presbyterian Hospital   (United States)

^s HOUSTON METHODIST HOSPITAL   (United States)

^t UNIVERSITY OF ZURICH   (Switzerland)

^u Roche Pharma Schweiz AG   (Switzerland)

more..

Author keywords

1p19q; oligoastrocytoma; oligodendroglioma; PCV; temozolomide

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; COHORT ANALYSIS; FEMALE; FRONTAL CORTEX; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; HUMANS; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862197898     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos065     Document Type: Article

References (18)

1. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988;23:360-364. (Pubitemid 18098242)
2. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-2714. (Pubitemid 46630566)
3. van den BentMJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J ClinOncol. 2006;24:2715-2722. (Pubitemid 46630567)
4. Cairncross G, Wang M, Chang S, et al. A randomized trial of chemotherapy plus radiotherapy (RT) versus RT alone for anaplastic oligodendroglioma (RTOG 9402): the perspective of longer follow-up [Abstact]. Int J Radiat Oncol Biol Phys. 2008;72:S7-S8.
5. RTOG. Chromosomal abnormality found to be a strong indicator for determining treatment and outcome for patients with oligodendroglioma brain tumors. 2012; http://www.rtog.org/News/tabid/72/articleType/ArticleView/ articleId/31/Chromosomal-Abnormality-Found-to-be-a-Strong-Indicator-for- Determining-Treatment-and-Outcomefor-Patients-with-Oligodendroglioma-Brain- Tumors.aspx. Accessed 1/20/2012.
6. National Cancer Institute. Genetic abnormality predicts benefit from treatment for a rare brain tumor: NCI press release. 2012; http://www.cancer. gov/newscenter/pressreleases/2012/Oligodendroglioma RTOG/print. Accessed 1/20/2012.
7. Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-oncol. 2007;9: 314-318. (Pubitemid 47169664)
8. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874-5880.
9. DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. J Clin Oncol. 2009;27:5861-5862.
10. Vogelbaum MA, Berkey B, Peereboom D, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009;11:167-175.
11. Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011;13:649-659.
12. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group [Erratum in J Clin Oncol 1999 Nov;17(11):3693]. J Clin Oncol. 1999;17:2762-2771. (Pubitemid 29415233)
13. Morris PG, Lassman AB. Medical oncology: optimizing chemotherapy and radiotherapy for anaplastic glioma. Nat Rev Clin Oncol. 2010;7:428-430.
14. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
15. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810-818.
16. Burger PC. What is an oligodendroglioma? Brain Pathol. 2002;12:257-259. (Pubitemid 34259927)
17. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: International Agency for Research on Cancer; 2007.
18. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597-1604.